Wang Longgui, Zou Xuanyi, Berger Aaron D, Twiss Christian, Peng Yi, Li Yirong, Chiu Jason, Guo Hongfeng, Satagopan Jaya, Wilton Andrew, Gerald William, Basch Ross, Wang Zhengxin, Osman Iman, Lee Peng
Am J Transl Res. 2009;1(1):62-71. Epub 2009 Jan 1.
Histone deacetetylases (HDACs) are a group of corepressors of transcriptional activators and their levels of expression are potentially dysregulated in prostate cancer. Certain inhibitors of histone deacetylases show anti-tumor activity in prostate cancer cell lines. Here, we systemically studied the expression of HDACs in human prostate cancer and the suppression of prostate cancer growth and invasion by HDAC inhibitor SAHA. HDAC1-5 showed increased expression using a combination of DNA microarray, in-situ hybridization, and immunohistochemistry in benign and malignant human prostate tissue as well as RT-PCR and Western blot analysis on various PCa cell lines. Importantly, HDAC inhibitor SAHA suppressed, in particular, prostate cancer cell growth and invasion determined using cell proliferation and Matrigel invasion assays. The findings of this study show that the expression of HDACs and their associated corepressors are increased in prostate cancer in humans and HDAC inhibitor SAHA could serve as a potential therapeutic agent in prostate cancer in addition to anti-androgens.
组蛋白去乙酰化酶(HDACs)是转录激活因子的一组共抑制因子,其表达水平在前列腺癌中可能失调。某些组蛋白去乙酰化酶抑制剂在前列腺癌细胞系中显示出抗肿瘤活性。在此,我们系统地研究了HDACs在人前列腺癌中的表达以及HDAC抑制剂SAHA对前列腺癌生长和侵袭的抑制作用。通过DNA微阵列、原位杂交和免疫组织化学相结合的方法,以及对各种前列腺癌细胞系进行RT-PCR和蛋白质印迹分析,发现HDAC1 - 5在良性和恶性人前列腺组织中的表达均增加。重要的是,HDAC抑制剂SAHA尤其抑制了通过细胞增殖和基质胶侵袭试验测定的前列腺癌细胞生长和侵袭。本研究结果表明,HDACs及其相关共抑制因子在人类前列腺癌中的表达增加,并且HDAC抑制剂SAHA除了抗雄激素外,还可作为前列腺癌的潜在治疗药物。